Compare AMPH & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPH | EVO |
|---|---|---|
| Founded | 1996 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.8M | 934.1M |
| IPO Year | 2005 | N/A |
| Metric | AMPH | EVO |
|---|---|---|
| Price | $17.16 | $2.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $28.38 | $7.00 |
| AVG Volume (30 Days) | ★ 568.2K | 95.9K |
| Earning Date | 05-07-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $719,887,000.00 | N/A |
| Revenue This Year | $6.90 | $1.37 |
| Revenue Next Year | $4.64 | $10.05 |
| P/E Ratio | $120.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.76 | $2.31 |
| 52 Week High | $31.26 | $4.80 |
| Indicator | AMPH | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 33.88 | 41.07 |
| Support Level | $17.03 | $2.32 |
| Resistance Level | $24.16 | $3.78 |
| Average True Range (ATR) | 0.86 | 0.09 |
| MACD | -0.60 | -0.06 |
| Stochastic Oscillator | 7.21 | 19.16 |
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.